Express News | Cullinan Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Target Price $40
ReutersMay 1 07:00 ET
Cullinan Oncology Initiated at Buy by Stifel
Cullinan Oncology Initiated at Buy by Stifel
Dow JonesMay 1 05:59 ET
Express News | Stifel Initiates Coverage On Cullinan Therapeutics With Buy Rating, Announces Price Target of $40
BenzingaMay 1 05:49 ET
Cullinan Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/01/2024 49.53% Stifel → $40 Initiates Coverage On → Buy 04/17/2024 -2.8% JonesTrading $22 → $26 Maintai
BenzingaMay 1 05:47 ET
Cullinan Therapeutics Appoints Mary Kay Fenton as CFO
Cullinan Therapeutics (CGEM) said Monday it has appointed Mary Kay Fenton as chief financial officer, effective immediately. Fenton has thirty years of financial and operational experience in the biot
MT NewswiresApr 29 15:19 ET
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister it
BenzingaApr 29 13:04 ET
Express News | Cullinan Therapeutics Shares Are Trading Higher. The Company Announced the Appointment of a New CFO
BenzingaApr 29 11:46 ET
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Nasdaq Composite jumping over 50 points on Monday.Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply during Monday's session on reports the company will partner with Ba
BenzingaApr 29 10:47 ET
Cullinan Therapeutics Appoints CFO
Seeking AlphaApr 29 07:58 ET
Express News | Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
ReutersApr 29 07:00 ET
Amgen's Blincyto Data Send Cullinan Higher
Cullinan Therapeutics (NASDAQ:CGEM) drew Wall Street's attention last week as William Blair touted the stock after peer-reviewed data for Amgen's (NASDAQ:AMGN) leukemia therapy, Blincyto, which targets CD19 surface antigens on B cells similar to CGEM's lymphoma candidate CLN-978.
Seeking AlphaApr 27 15:39 ET
Express News | Cullinan Therapeutics Shares Are Trading Higher. The Company This Week Announced That Clinical Data From Its Phase 1 Trial of CLN-619 in Patients With Advanced Solid Tumors Will Be Presented at the 2024 ASCO Annual Meeting
BenzingaApr 26 14:27 ET
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Aon plc (NYSE:AON) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Aon posted adjusted earnings of $5.66 per share, missing ma
BenzingaApr 26 13:56 ET
PEGY, CGEM and IFBD Among Mid-day Movers
Seeking AlphaApr 26 13:09 ET
Cullinan Therapeutics Up Over 27%, On Pace for Record Percent Increase -- Data Talk
Cullinan Therapeutics, Inc. (CGEM) is currently at $24.48, up $5.23 or 27.17% --Would be highest close since Oct. 15, 2021, when it closed at $25.00 --Would be largest percent increase on record (Ba
Dow JonesApr 26 12:51 ET
12 Health Care Stocks Moving In Friday's Intraday Session
GainersBiodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 61.4% to $1.17 during Friday's regular session. The company's market cap stands at $5.1 million. Agenus (NASDAQ:AGEN) shares rose 32.53% to $11.
BenzingaApr 26 12:31 ET
Express News | Cullinan Therapeutics Inc : Jonestrading Raises Target Price to $29 From $26
ReutersApr 26 11:18 ET
Skechers +13%, Reports Upbeat Earnings, Joins These Climbing Stocks
U.S. stocks were higher, with the Dow Jones jumping over 150 points on Friday.Shares of Skechers U.S.A., Inc. (NYSE:SKX) rose sharply during Friday's session after the company reported better-than-exp
BenzingaApr 26 10:45 ET
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
A recent academic case study, published on April 22, examined using Amgen Inc's (NASDAQ:AMGN) Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with severe systemic sclerosis. The fin
BenzingaApr 24 14:29 ET
Express News | Cullinan Therapeutics Shares Are Trading Higher After the Company Announced That Clinical Data From Its Phase 1 Trial of CLN-619 in Patients With Advanced Solid Tumors Will Be Presented at the 2024 ASCO Annual Meeting
Moomoo 24/7Apr 24 12:22 ET
No Data
No Data